Founders Capital Management Geron Corp Transaction History

Founders Capital Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 05, 2018	SELL	$1.76 - $6.38 $5,280 - $19,140	-3,000 Closed	0 $0
Q2 2018 Jul 09, 2018	SELL	$3.29 - $4.82 $3,290 - $4,820	-1,000 Reduced 25.0%	3,000 $10,000
Q3 2017 Oct 17, 2017	BUY	$1.99 - $2.65 $7,960 - $10,600	4,000	4,000 $9,000

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.28B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

Stay updated on Founders Capital Management with notifications on news.